{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,29]],"date-time":"2025-12-29T14:14:14Z","timestamp":1767017654785,"version":"3.48.0"},"reference-count":41,"publisher":"Oxford University Press (OUP)","issue":"1","license":[{"start":{"date-parts":[[2025,9,13]],"date-time":"2025-09-13T00:00:00Z","timestamp":1757721600000},"content-version":"vor","delay-in-days":255,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,1,6]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Abstract<\/jats:title>\n                    <jats:p>BackgroundGlioma patients may require long-term anticoagulation for comorbidities, including arrhythmias or venous thromboembolism (VTE). While direct oral anticoagulants (DOACs) have demonstrated safety in general cancer populations, safety data for glioma patients remains limited. The aim of this study was to assess intracerebral hemorrhage (ICH) risk with DOAC compared to low molecular weight heparin (LMWH) in glioma patients.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We reviewed adult patients with primary glioma who received DOAC and\/or LMWH for at least 10 days between 2008 and 2023 across Cleveland Clinic Health System hospitals. ICH rates and severity were compared between treatment groups.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Among 277 patients (147 DOAC, 130 LMWH), median time from tumor diagnosis to first VTE was 70 days, with 32% experiencing VTE within six months of glioma diagnosis. Of these, 74% had glioblastoma. No statistically significant difference in ICH risk was found between DOAC and LMWH groups (P\u2009=\u2009.3) or across tumor grades (P\u2009=\u2009.6). Six ICH events occurred: three trace\/minor, one subdural, and two major\/fatal (both in LMWH patients). Five events occurred in glioblastoma patients and one in a patient with oligodendroglioma.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>This observational study suggests DOACs are relatively safe in glioma patients given the low ICH risk. While most ICH events occurred in glioblastoma patients, no significant difference in risk was found across tumor grades. Prospective studies will establish anticoagulation risks in this population.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/noajnl\/vdaf205","type":"journal-article","created":{"date-parts":[[2025,9,11]],"date-time":"2025-09-11T12:01:22Z","timestamp":1757592082000},"source":"Crossref","is-referenced-by-count":0,"title":["Intracerebral hemorrhage risk in glioma patients taking direct oral anticoagulants as compared with low molecular weight heparin"],"prefix":"10.1093","volume":"7","author":[{"ORCID":"https:\/\/orcid.org\/0009-0004-8012-6929","authenticated-orcid":false,"given":"Radhika S","family":"Amin","sequence":"first","affiliation":[{"name":"School of Medicine, Case Western Reserve University , Cleveland, Ohio"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Scott","family":"Cameron","sequence":"additional","affiliation":[{"name":"Cleveland Clinic Lerner College of Medicine, Case Western Reserve University , Cleveland, Ohio"},{"name":"Cleveland Clinic Research, Cleveland Clinic, Cleveland, Ohio"},{"name":"Heart, Vascular, and Thoracic Institute, Cleveland Clinic , Cleveland, Ohio"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Matthew M","family":"Grabowski","sequence":"additional","affiliation":[{"name":"Cleveland Clinic Lerner College of Medicine, Case Western Reserve University , Cleveland, Ohio"},{"name":"Rose Ella Burkhardt Brain Tumor and Neuro-Oncology Center, Cleveland Clinic , Cleveland, Ohio"},{"name":"Cleveland Clinic Research, Cleveland Clinic, Cleveland, Ohio (S.C., M.M.G., J.D.L., A.R.S.)"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3168-7290","authenticated-orcid":false,"given":"Justin D","family":"Lathia","sequence":"additional","affiliation":[{"name":"Cleveland Clinic Lerner College of Medicine, Case Western Reserve University , Cleveland, Ohio"},{"name":"Rose Ella Burkhardt Brain Tumor and Neuro-Oncology Center, Cleveland Clinic , Cleveland, Ohio"},{"name":"Department of Cancer Sciences, Cleveland Clinic Research, Case Comprehensive Cancer Center , Cleveland, Ohio"},{"name":"Cleveland Clinic Research, Cleveland Clinic , Cleveland, Ohio"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mina","family":"Lobbous","sequence":"additional","affiliation":[{"name":"Cleveland Clinic Lerner College of Medicine, Case Western Reserve University , Cleveland, Ohio"},{"name":"Rose Ella Burkhardt Brain Tumor and Neuro-Oncology Center, Cleveland Clinic , Cleveland, Ohio"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mark G","family":"Malkin","sequence":"additional","affiliation":[{"name":"Cleveland Clinic Lerner College of Medicine, Case Western Reserve University , Cleveland, Ohio"},{"name":"Rose Ella Burkhardt Brain Tumor and Neuro-Oncology Center, Cleveland Clinic , Cleveland, Ohio"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David M","family":"Peereboom","sequence":"additional","affiliation":[{"name":"Cleveland Clinic Lerner College of Medicine, Case Western Reserve University , Cleveland, Ohio"},{"name":"Rose Ella Burkhardt Brain Tumor and Neuro-Oncology Center, Cleveland Clinic , Cleveland, Ohio"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7994-3316","authenticated-orcid":false,"given":"Anthony R","family":"Sloan","sequence":"additional","affiliation":[{"name":"Cleveland Clinic Research, Cleveland Clinic, Cleveland, Ohio"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Glen H J","family":"Stevens","sequence":"additional","affiliation":[{"name":"Cleveland Clinic Lerner College of Medicine, Case Western Reserve University , Cleveland, Ohio"},{"name":"Rose Ella Burkhardt Brain Tumor and Neuro-Oncology Center, Cleveland Clinic , Cleveland, Ohio"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alejandro","family":"Torres-Trejo","sequence":"additional","affiliation":[{"name":"Cleveland Clinic Lerner College of Medicine, Case Western Reserve University , Cleveland, Ohio"},{"name":"Rose Ella Burkhardt Brain Tumor and Neuro-Oncology Center, Cleveland Clinic , Cleveland, Ohio"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Surabhi","family":"Ranjan","sequence":"additional","affiliation":[{"name":"Department of Neurosurgery, Cleveland Clinic Florida , Weston, Florida"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5027-1277","authenticated-orcid":true,"given":"Andrew","family":"Dhawan","sequence":"additional","affiliation":[{"name":"Cleveland Clinic Lerner College of Medicine, Case Western Reserve University , Cleveland, Ohio"},{"name":"Rose Ella Burkhardt Brain Tumor and Neuro-Oncology Center, Cleveland Clinic , Cleveland, Ohio"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2025,9,13]]},"reference":[{"key":"2025122909121084900_vdaf205-B1","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1016\/j.thromres.2015.11.027","article-title":"Recurrent venous thromboembolism in glioblastoma","volume":"137","author":"Edwin","year":"2016","journal-title":"Thromb Res"},{"key":"2025122909121084900_vdaf205-B2","doi-asserted-by":"publisher","first-page":"601","DOI":"10.3171\/jns.2007.106.4.601","article-title":"Epidemiology of venous thromboembolism in 9489 patients with malignant glioma","volume":"106","author":"Semrad","year":"2007","journal-title":"J Neurosurg"},{"key":"2025122909121084900_vdaf205-B3","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1055\/s-0034-1370791","article-title":"Thrombosis in brain tumors","volume":"40","author":"Jo","year":"2014","journal-title":"Semin Thromb Hemost"},{"key":"2025122909121084900_vdaf205-B4","doi-asserted-by":"publisher","first-page":"e2678","DOI":"10.7759\/cureus.2678","article-title":"Risk of venous thromboembolism in glioblastoma patients","volume":"10","author":"Lim","year":"2018","journal-title":"Cureus"},{"key":"2025122909121084900_vdaf205-B5","doi-asserted-by":"publisher","first-page":"1414","DOI":"10.3390\/cells10061414","article-title":"Contrasts in glioblastoma\u2014venous thromboembolism versus bleeding risk","volume":"10","author":"Muster","year":"2021","journal-title":"Cells"},{"key":"2025122909121084900_vdaf205-B6","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1093\/noajnl\/vdaf018","article-title":"VTE incidence shortens survival in IDH-WT glioblastoma","volume":"31","author":"Sloan","year":"2025","journal-title":"Neuro-Oncol Adv."},{"key":"2025122909121084900_vdaf205-B7","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1016\/j.hest.2022.01.005","article-title":"Opinion: hemorrhage in brain tumor\u2014an unresolved issue","volume":"3","author":"Ostrowski","year":"2022","journal-title":"Brain Hemorrhages"},{"key":"2025122909121084900_vdaf205-B8","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1160\/TH16-09-0680","article-title":"Outcomes of low-molecular-weight heparin treatment for venous thromboembolism in patients with primary and metastatic brain tumours","volume":"117","author":"Chai-Adisaksopha","year":"2017","journal-title":"Thromb Haemost"},{"key":"2025122909121084900_vdaf205-B9","doi-asserted-by":"publisher","first-page":"e1063","DOI":"10.1212\/WNL.0000000000011414","article-title":"Risk of venous thromboembolism in grade II\u2013IV gliomas as a function of molecular subtype","volume":"96","author":"Diaz","year":"2021","journal-title":"Neurology"},{"key":"2025122909121084900_vdaf205-B10","doi-asserted-by":"publisher","first-page":"e191","DOI":"10.1161\/CIRCULATIONAHA.114.010426","article-title":"Warfarin versus novel oral anticoagulants","volume":"130","author":"Wadhera","year":"2014","journal-title":"Circulation"},{"key":"2025122909121084900_vdaf205-B11","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1016\/j.ahj.2015.03.017","article-title":"Patients\u2019 time in therapeutic range on warfarin among US patients with atrial fibrillation: Results from ORBIT-AF registry","volume":"170","author":"Pokorney","year":"2015","journal-title":"Am Heart J"},{"key":"2025122909121084900_vdaf205-B12","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1016\/j.thromres.2018.02.144","article-title":"Direct oral anticoagulant (DOAC) versus low-molecular-weight heparin (LMWH) for treatment of cancer associated thrombosis (CAT): a systematic review and meta-analysis","volume":"173","author":"Li","year":"2019","journal-title":"Thromb Res"},{"key":"2025122909121084900_vdaf205-B13","doi-asserted-by":"publisher","first-page":"824","DOI":"10.1161\/ATVBAHA.123.318779","article-title":"Updates in the incidence, pathogenesis, and management of cancer and venous thromboembolism","volume":"43","author":"Girardi","year":"2023","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"2025122909121084900_vdaf205-B14","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1056\/NEJMoa025313","article-title":"Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer","volume":"349","author":"Lee","year":"2003","journal-title":"N Engl J Med"},{"key":"2025122909121084900_vdaf205-B15","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1007\/s11239-019-01833-w","article-title":"Low-molecular-weight-heparin versus a coumarin for the prevention of recurrent venous thromboembolism in high- and low-risk patients with active cancer: a post hoc analysis of the CLOT study","volume":"47","author":"Woodruff","year":"2019","journal-title":"J Thromb Thrombolysis"},{"key":"2025122909121084900_vdaf205-B16","doi-asserted-by":"publisher","first-page":"CD006650","DOI":"10.1002\/14651858.CD006650.pub5","article-title":"Anticoagulation for the long-term treatment of venous thromboembolism in people with cancer","volume":"6","author":"Kahale","year":"2018","journal-title":"Cochrane Database Syst Rev"},{"key":"2025122909121084900_vdaf205-B17","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1111\/jth.14662","article-title":"Apixaban and dalteparin in active malignancy-associated venous thromboembolism: the ADAM VTE trial","volume":"18","author":"McBane","year":"2020","journal-title":"J Thromb Haemost JTH"},{"key":"2025122909121084900_vdaf205-B18","doi-asserted-by":"publisher","first-page":"1599","DOI":"10.1056\/NEJMoa1915103","article-title":"Apixaban for the treatment of venous thromboembolism associated with cancer","volume":"382","author":"Agnelli","year":"2020","journal-title":"N Engl J Med"},{"key":"2025122909121084900_vdaf205-B19","doi-asserted-by":"publisher","first-page":"2017","DOI":"10.1200\/JCO.2018.78.8034","article-title":"Comparison of an oral factor Xa inhibitor with low molecular weight heparin in patients with cancer with venous thromboembolism: results of a randomized trial (SELECT-D)","volume":"36","author":"Young","year":"2018","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"key":"2025122909121084900_vdaf205-B20","doi-asserted-by":"publisher","first-page":"615","DOI":"10.1056\/NEJMoa1711948","article-title":"Edoxaban for the treatment of cancer-associated venous thromboembolism","volume":"378","author":"Raskob","year":"2018","journal-title":"N Engl J Med"},{"key":"2025122909121084900_vdaf205-B21","doi-asserted-by":"publisher","first-page":"e37-46","DOI":"10.1016\/S2352-3026(14)70018-3","article-title":"Oral rivaroxaban versus enoxaparin with vitamin K antagonist for the treatment of symptomatic venous thromboembolism in patients with cancer (EINSTEIN-DVT and EINSTEIN-PE): a pooled subgroup analysis of two randomised controlled trials","volume":"1","author":"Prins","year":"2014","journal-title":"Lancet Haematol"},{"key":"2025122909121084900_vdaf205-B22","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1186\/s13045-022-01289-1","article-title":"Direct oral anticoagulant versus low molecular weight heparin for the treatment of cancer-associated venous thromboembolism: 2022 updated systematic review and meta-analysis of randomized controlled trials","volume":"15","author":"Frere","year":"2022","journal-title":"J Hematol OncolJ Hematol Oncol"},{"key":"2025122909121084900_vdaf205-B23","doi-asserted-by":"publisher","first-page":"18945","DOI":"10.1038\/s41598-020-75863-3","article-title":"Efficacy and safety of direct oral anticoagulants for secondary prevention of cancer associated throm\u00adbosis: a meta-analysis of randomized controlled trials","volume":"10","author":"Desai","year":"2020","journal-title":"Sci Rep"},{"key":"2025122909121084900_vdaf205-B24","doi-asserted-by":"publisher","first-page":"1439","DOI":"10.1055\/s-0038-1667001","article-title":"Clinical impact of bleeding in cancer-associated venous thromboembolism: Results from the hokusai VTE cancer study","volume":"118","author":"Kraaijpoel","year":"2018","journal-title":"Thromb Haemost"},{"key":"2025122909121084900_vdaf205-B25","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1111\/jth.14336","article-title":"Intracranial hemorrhage with direct oral anticoagulants in patients with brain tumors","volume":"17","author":"Carney","year":"2019","journal-title":"J Thromb Haemost"},{"key":"2025122909121084900_vdaf205-B26","doi-asserted-by":"publisher","first-page":"6291","DOI":"10.1182\/bloodadvances.2020003238","article-title":"Intracranial hemorrhage with direct oral anticoagulants in patients with brain metastases","volume":"4","author":"Leader","year":"2020","journal-title":"Blood Adv"},{"key":"2025122909121084900_vdaf205-B27","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1002\/onco.13698","article-title":"Safety of direct oral anticoagulants in Central nervous system malignancies","volume":"26","author":"Swartz","year":"2021","journal-title":"Oncologist"},{"key":"2025122909121084900_vdaf205-B28","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1016\/j.thromres.2021.10.023","article-title":"Direct oral anticoagulants or low-molecular-weight heparins for venous thromboembolism in patients with brain tumors","volume":"208","author":"Lee","year":"2021","journal-title":"Thromb Res"},{"key":"2025122909121084900_vdaf205-B29","doi-asserted-by":"publisher","first-page":"496","DOI":"10.1200\/JCO.19.01461","article-title":"Venous thromboembolism prophylaxis and treatment in patients with cancer: ASCO clinical practice guideline update","volume":"38","author":"Key","year":"2020","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"key":"2025122909121084900_vdaf205-B30","doi-asserted-by":"publisher","first-page":"555","DOI":"10.1016\/j.thromres.2005.10.015","article-title":"Chemotherapy-induced thrombosis","volume":"118","author":"Haddad","year":"2006","journal-title":"Thromb Res"},{"key":"2025122909121084900_vdaf205-B31","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1007\/s11060-015-1840-z","article-title":"A prospective multicenter study of venous thromboembolism in patients with newly-diagnosed high-grade glioma: hazard rate and risk factors","volume":"124","author":"Streiff","year":"2015","journal-title":"J Neurooncol"},{"key":"2025122909121084900_vdaf205-B32","doi-asserted-by":"publisher","first-page":"1322","DOI":"10.1182\/blood.2022017858","article-title":"Determining venous thromboembolism risk in patients with adult-type diffuse glioma","volume":"141","author":"Burdett","year":"2023","journal-title":"Blood"},{"key":"2025122909121084900_vdaf205-B33","doi-asserted-by":"publisher","first-page":"vdac172","DOI":"10.1093\/noajnl\/vdac172","article-title":"Glioma stem cells activate platelets by plasma-independent thrombin production to promote glioblastoma tumorigenesis","volume":"4","author":"Sloan","year":"2022","journal-title":"Neurooncol Adv"},{"key":"2025122909121084900_vdaf205-B34","doi-asserted-by":"publisher","first-page":"2172","DOI":"10.1093\/neuonc\/noac125","article-title":"Risk of intracranial hemorrhage with direct oral anticoagulants vs low molecular weight heparin in glioblastoma: a retrospective cohort study","volume":"24","author":"Reed-Guy","year":"2022","journal-title":"Neuro-Oncol"},{"key":"2025122909121084900_vdaf205-B35","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1016\/j.jtha.2023.10.011","article-title":"Comparison of direct oral anticoagulants versus low-molecular-weight heparin in primary and metastatic brain cancers: a meta-analysis and systematic review","volume":"22","author":"Iyengar","year":"2024","journal-title":"J Thromb Haemost JTH"},{"key":"2025122909121084900_vdaf205-B36","doi-asserted-by":"publisher","first-page":"6419","DOI":"10.3390\/curroncol29090505","article-title":"Practical considerations for the management of cancer-associated venous thromboembolism: a guide for the general oncology practitioner","volume":"29","author":"Harrigan","year":"2022","journal-title":"Curr Oncol Tor Ont"},{"key":"2025122909121084900_vdaf205-B37","doi-asserted-by":"publisher","first-page":"286","DOI":"10.5482\/HAMO-17-01-0003","article-title":"DOAC use in patients with chronic kidney disease","volume":"37","author":"Kc\u00fckk\u00f6yl\u00fc","year":"2017","journal-title":"Hamostaseologie"},{"key":"2025122909121084900_vdaf205-B38","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1007\/s40263-023-00990-0","article-title":"Interactions between direct oral anticoagulants (DOACs) and antiseizure medications: potential implications on DOAC treatment","volume":"37","author":"Goldstein","year":"2023","journal-title":"CNS Drugs"},{"key":"2025122909121084900_vdaf205-B39","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1093\/nop\/npab030","article-title":"Efficacy of antiepileptic drugs in glioma patients with epilepsy: a systematic review","volume":"8","author":"de Bruin","year":"2021","journal-title":"Neurooncol Pract"},{"key":"2025122909121084900_vdaf205-B40","doi-asserted-by":"publisher","first-page":"386","DOI":"10.1007\/s11239-019-02032-3","article-title":"Inpatient and outpatient treatment patterns of cancer-associated thrombosis in the United States","volume":"50","author":"Guo","year":"2020","journal-title":"J Thromb Thrombolysis"},{"key":"2025122909121084900_vdaf205-B41","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1002\/rth2.12002","article-title":"Current practice patterns and patient persistence with anticoagulant treatments for cancer-associated thrombosis","volume":"1","author":"Khorana","year":"2017","journal-title":"Res Pract Thromb Haemost"}],"container-title":["Neuro-Oncology Advances"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/noa\/advance-article-pdf\/doi\/10.1093\/noajnl\/vdaf205\/64262489\/vdaf205.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/noa\/article-pdf\/7\/1\/vdaf205\/64262489\/vdaf205.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/noa\/article-pdf\/7\/1\/vdaf205\/64262489\/vdaf205.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,29]],"date-time":"2025-12-29T14:12:18Z","timestamp":1767017538000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/noa\/article\/doi\/10.1093\/noajnl\/vdaf205\/8253629"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1]]},"references-count":41,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,1,6]]}},"URL":"https:\/\/doi.org\/10.1093\/noajnl\/vdaf205","relation":{},"ISSN":["2632-2498"],"issn-type":[{"type":"electronic","value":"2632-2498"}],"subject":[],"published-other":{"date-parts":[[2025,1]]},"published":{"date-parts":[[2025,1]]},"article-number":"vdaf205"}}